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(ABSTRACT) 
 
Improvements in sensor accuracy, greater convenience and ease of use and expanding 
reimbursement have led to growing adoption of continuous glucose monitoring (CGM). 
However, successful utilization of CGM technology in routine clinical practice remains 
relatively low. This may be due in part to the lack of clear and agreed upon glycemic targets that 
both diabetes teams and people with diabetes can work towards. Although unified 
recommendations for use of key CGM metrics have been established in three separate peer 
reviewed articles, formal adoption by diabetes professional organizations, and guidance in the 
practical application of these metrics in clinical practice has been lacking. In February 2019, the 
Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international 
panel of physicians, researchers, and individuals with diabetes who are expert in CGM 
technologies to address this issue. This article summarizes the ATTD consensus 
recommendations for relevant aspects of CGM data utilization and reporting among the various 
diabetes populations. 
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Adoption of continuous glucose monitoring (CGM), which includes both real-time CGM 
(rtCGM) and intermittently-scanned CGM (isCGM), has grown rapidly over the past few years 
due to improvements in sensor accuracy, greater convenience and ease of use and expanding 
reimbursement. Numerous studies have demonstrated significant clinical benefits of CGM use in 
people with diabetes regardless of insulin delivery method (1-15). In many countries, the benefits 
and utility of CGM are now recognized by national and international medical organizations for 
individuals with insulin-requiring diabetes and/or those at risk for hypoglycemia (16-21). 
However, despite increased CGM adoption (22; 23), successful utilization of CGM data in 
routine clinical practice remains relatively low. This may be due in part to the lack of clear and 
agreed upon glycemic targets toward which both diabetes teams and people with diabetes can 
work.  
In 2012 the Helmsley Charitable Trust sponsored the first expert panel to recommend the 
standardization of CGM metrics and CGM report visualization (24). This was followed by a 
series of CGM consensus statements refining the core CGM metrics but the conclusions were 
never in alignment. In 2017, several articles supported use of systematic approaches to CGM 
data evaluation (18-20). To date, the key CGM metrics remain as unified recommendations in 
three separate peer reviewed articles, yet formal adoption by diabetes professional organizations 
and guidance in the practical application of these metrics in clinical practice has been lacking 
(19). 
In February 2019, the Advanced Technologies and Treatments for Diabetes (ATTD) 
Congress convened an international panel of individuals with diabetes and clinicians and 
researchers expert in CGM. Our objective was to develop evidence-based, clinical CGM targets 
to supplement the currently agreed-upon metrics for CGM derived times in glucose ranges 
(within target range, below target range, above target range) in order to provide guidance for 
clinicians, researchers, and individuals with diabetes in utilizing, interpreting and reporting CGM 
data in routine clinical care and research. Importantly, in order to make the recommendations 
generalizable and comprehensive, the consensus panel included individuals living with diabetes 
and had international representation from physicians and researchers from all geographic 
regions.  
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 The panel was divided into subgroups to review literature and provide evidence-based 
recommendations for relevant aspects of CGM data utilization and reporting among the various 
diabetes populations. Because long-term trials demonstrating how CGM metrics relate to and/or 
predict clinical outcomes have not been conducted, there is suggestive evidence from a number 
of recent studies, one a cross-sectional study correlating current retrospective 3-day TIR with 
varying degrees of diabetes retinopathy (25) and an analysis of the 7-point SMBG data from the 
DCCT (26) have shown correlations of time in target range (70-180 mg/dL [3.9-10.0 mmol/L]) 
with diabetes complication.  Relationships between time in target range and A1C (25; 26) and 
number of severe and non-severe hypoglycemic events (27-31) have also been observed.  
Recommendations from each subgroup were then presented to the full panel and voted upon. 
This article summarizes the consensus UHFRPPHQGDWLRQVDQGUHSUHVHQWVWKHSDQHOPHPEHUV¶
evaluation of the issues. 
 
Need for Metrics Beyond A1C 
A1C is currently recognized as the key surrogate marker for the development of long-
term diabetes complications in people with type 1 and type 2 diabetes and has been used the 
primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33). While A1C reflects the average 
glucose over the last 2-3 months, its limitation is the lack of  information about acute glycemic 
excursions and the acute complications of  hypo- and hyperglycemia. A1C also fails to identify 
the magnitude and frequency of intra- and inter-day glucose variation (34; 35). Moreover, certain 
conditions such as anemia (36), hemoglobinopathies (37), iron deficiency (38), and pregnancy 
(39) can confound A1C measurements. Importantly, as reported by Beck and colleagues, the 
A1C test can at times fail to accurately reflect mean glucose even when none of these conditions 
are present (40). Despite these limitations, A1C is the only prospectively evaluated tool for 
assessing the risk for diabetes complications and its importance in clinical decision-making 
should not be undervalued. Rather, the utility of A1C is further enhanced when used in 
combination with CGM data.   
Unlike A1C measurement, use of CGM allows for the direct observation of glycemic 
excursions and daily profiles, which can inform on immediate therapy decisions and/or lifestyle 
modifications. CGM also provides the ability to assess glucose variability (GV) and identify 
patterns of hypo- and hyperglycemia.  
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 Effective use of CGM data to optimize clinical outcomes requires the user to interpret the 
collected data and act upon them appropriately. This requires: 1) common metrics for assessment 
of CGM glycemic status; 2) graphical visualization of the glucose data and CGM daily profile; 
and 3) clear evidence-based clinical targets. 
 
Standardization of CGM Metrics 
In February 2017, the Advanced Technologies and Treatments for Diabetes (ATTD) 
Congress convened an international panel of expert clinicians and researchers to define core 
metrics for assessing CGM data (18). (Table 1)  
 
Table 1. Standardized CGM Metrics 
2017 International Consensus on CGM Metrics (18) 
 1. Number of Days CGM Worn  
 2. Percentage of time CGM is active  
 3. Mean Glucose 
 4. Estimated A1c (eA1C) 
 5. Glycemic Variability (%CV or SD) 
 6. Time >250 mg/dL (>13.9 mmol/L)  
 7. Time >180 mg/dL (>10.0 mmol/L)  
 8. Time 70-180 mg/dL (3.9-10.0 mmol/L) 
 9. Time <70 mg/dL (<3.9 mmol/L)  
10. Time <54 mg/dL (<3.0 mmol/L)  
11. LBGI & HBGI (risk indices) 
12. Episodes (hypoglycemia and hyperglycemia) 15 min 
13. Area under the curve (AUC) 
14. Time Blocks (24-h, day, night) 
Use of Ambulatory Glucose Profile (AGP) for CGM report 
 CV=Coefficient of variation; SD=standard deviation; LBGI=low blood glucose index; HBGI=high blood glucose index. 
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 The list of core CGM metrics has now been streamlined for use in clinical practice based 
on the expert opinion of this International Consensus Group (18). Of the 14 core metrics, the 
panel selected that 10 metrics that may be most useful in clinical practice (Table 2).     
 
Table 2. Standardized CGM Metrics for Clinical Care 
2019 Core CGM Metrics for Clinical Care  (18) 
 1. Number of Days CGM Worn (recommend 14 days) (41; 42) 
 
 2. Percentage of time CGM is active (recommend 70% of data from 14 days) (41; 42). 
 3. Mean Glucose 
 4. Glucose Management Indicator (GMI) (43) 
 5. Glycemic Variability (%CV) Target <36% (44)* 
 6. Time Above Range (TAR) -  % of readings and time >250 mg/dL (>13.9 mmol/L)                    Level 2 
 7. Time Above Range (TAR) -  % of readings and time 181-250 mg/dL (10.1-13.9 mmol/L)          
 
Level 1 
 8. Time In Range (TIR)  -  % of readings and time 70-180 mg/dL (3.9-10.0 mmol/L)                 
 
In Range 
 9. Time Below Range (TBR) -  % of readings and time 54-69 mg/dL (3.0-3.8 mmol/L)                   
 
Level 1 
10. Time Below Range (TBR) - % of readings and time <54 mg/dL (<3.0 mmol/L)                      
 
Level 2 
Use of Ambulatory Glucose Profile (AGP) for CGM report 
 CV=Coefficient of variation; SD=standard deviation; LBGI=low blood glucose index; HBGI=high blood glucose index. 
* Some studies suggest that lower %CV targets (<33%) provide additional protection against hypoglycemia for 
those receiving insulin or sulfonylureas: <33% (44-46) 
 
Fundamental to accurate and meaningful interpretation of CGM is ensuring that adequate 
glucose data are available for evaluation. As shown in studies, >70% use of CGM over the recent 
14 days correlates strongly with 3 months of mean glucose, time in ranges, and hyperglycemia 
metrics (41; 42). In individuals with type 1 diabetes, correlations are weaker for hypoglycemia 
and glycemic variability; however, these correlations have not been shown to increase with 
longer sampling periods (42). Longer CGM data collection periods may be required for 
individuals with more variable glycemic control (e.g., 4 weeks of data to investigate 
hypoglycemia exposure). 
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Time in Ranges  
The development of blood glucose testing in 1965 provided individuals with diabetes the 
ability to obtain immediate information about their current glucose levels and adjust their therapy 
accordingly. Over the past decades, national and international medical organization have been 
successful in developing, harmonizing, and disseminating standardized glycemic targets based 
on risk for acute and chronic complications. CGM technology greatly expands the ability to 
assess glycemic control throughout the day, presenting critical data to inform daily treatment 
decisions and quantifying time below, within, and above the established glycemic targets.  
Although each of the core metrics established in the 2017 ATTD consensus conference 
(18) provides important information about various aspects of glycemic status, it is often 
impractical to assess and fully utilize many of these metrics in real-world clinical practices. To 
streamline data interpretation, the consensus panel identified ³WLPHLQUDQJHV´DVDFRPSRVLWH
metric of glycemic control that provides more actionable information than A1C alone. The panel 
agreed that establishing target percentages of time in the various glycemic ranges with the ability 
to adjust the percentage cutpoints to address the specific needs of special diabetes populations 
(e.g., pregnancy, high-risk) would facilitate safe and effective therapeutic decision-making 
within the parameters of the established glycemic goals.  
The composite metric includes three key CGM measurements: percentage of reading and 
time per day within target glucose range (TIR), time below target glucose range (TBR), and time 
above target glucose range (TAR) (Table 3). The primary goal for effective and safe glucose 
control is to increase the TIR while reducing the TBR. The consensus group agreed that 
expressing time in the various ranges can be done as the percentage (%) of CGM, average hours 
and minutes spent in each range or both, depending on the circumstances.  
It was agreed that CGM based glycemic targets must be personalized to meet the needs of 
each individual with diabetes. In addition, the group reached consensus on glycemic cutpoints (a 
target range of 70-180 mg/dL [3.9-10.0 mmol/L] for individuals with type 1 diabetes and type 2 
diabetes and 63-140 mg/dL [3.5-7.8 mmol/L] during pregnancy, along with a set of targets for 
the time per day [% of CGM readings or minutes/hrs]) individuals with type 1 diabetes and type 
2 diabetes (Table 3) and women during pregnancy (Table 4) should strive to achieve. It should 
be noted that premeal and postprandial targets remain for diabetes in pregnancy (ADA Standards 
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of medical care-2019. Diabetes Care 2019: 42 (Suppl 1)) in addition to the new TIR targets for 
overall glycemia. 
 
 
 
 
Table 3. Recommended cutpoints for assessment of glycemic control: Type 1 / Type 2 and 
Older / High-Risk Individuals 
 
Diabetes 
Group 
Time in Range (TIR) Time Below Range (TBR) Time Above Range (TAR) 
% of readings 
time/day 
Target 
Range 
% of readings 
time /day 
Below Target 
Level 
% of readings 
time/ day 
Above Target 
Level 
Type 1* / Type 2 
>70%         
>16hr, 48 min 
70-180 mg/dL 
3.9 -10.0 mmol/L 
<4% 
<1 hr 
<70 mg/dL 
<3.9 mmol/L 
<25% 
<6 hr 
>180 mg/dL 
>10.0 mmol/L 
<1% 
<15 min 
<54 mg/dL 
<3.0 mmol/L 
<5% 
<1 hr, 12 min 
>250 mg/dL 
>13.9 mmol/L 
Older/High-Risk 
Type 1 / Type 2 
>50% 
>12 hr 
70-180 mg/dL 
3.9-10 mmol/L 
<1% 
<15 min 
<70 mg/dL 
<3.9 mmol/L 
<10% 
<2 hr, 24 min 
>250 mg/dL 
>13.9 mmol/L 
Each incremental 5% increase in TIR is associated with clinically significant benefits for              
Type 1 / Type 2 (25; 26) 
* For age <25 yr., if the A1C goal is 7.5%  then set TIR target to ĂƉƉƌŽǆŝŵĂƚĞůǇ ? ?A? ? ?^ĞĞ “ůŝŶŝĐĂůƉƉůŝĐĂƚŝŽŶƐŽĨdŝŵĞƐ
ŝŶZĂŶŐĞ ? in the text for additional information regarding target goal setting in pediatric management) 
 
 
 Table 4. Consensus guidance on cutpoints for assessment of glycemic control: Pregnancy 
 
Diabetes 
Group 
Time in Range (TIR) Time Below Range (TBR) Time Above Range (TAR) 
% of readings 
time/day 
Target 
Range 
% of readings 
time /day 
Below Target 
Level 
% of readings 
time/ day 
Above Target 
Level 
Pregnancy    
Type 1 § 
>70% 
>16 hr, 48 min 
63-140 mg/dL ? 
3.5-7.8 mmol/L ? 
<4% 
<1 hr 
<63 mg/dL ? 
<3.5 mmol/L ? <25% 
<6 hr 
>140 mg/dL 
>7.8 mmol/L <1% 
<15 min 
<54 mg/dL 
<3.0 mmol/L 
Pregnancy §   
Type 2 / GDM 
see Pregnancy 
section 
63- ? ? ?ŵŐ ?Ě> ? 
3.5- ? ? ?ŵŵŽů ?> ? 
 see Pregnancy 
section 
AM ? ?ŵŐ ?Ě> ? 
<3.5 ŵŵŽů ?> ?  see Pregnancy 
section 
>140 mg/dL 
>7.8 mmol/L <54 mg/dL 
<3.0 mmol/L 
Each incremental 5% increase in TIR is associated with clinically significant benefits for              
Pregnancy Type 1 (47; 48) 
 輀 Glucose levels are physiologically lower during pregnancy 
§ Percentages of time in range are based on limited evidence. More research is needed.  
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Although the composite metric includes TIR, TBR and TAR, achieving the TBR and TIR 
goals would result in reduced time spent above range and thereby improve glycemic control. 
However, some clinicians may choose to target the reduction of the high glucose values and 
minimize hypoglycemia, thereby arriving at more time in the target range. In both approaches, 
the first priority is to reduce TBR to target levels and then address TIR or TAR targets.  
 Note that for people with type 1 diabetes, the targets are informed by the ability to reach 
the targets with hybrid closed-loop therapy (11), the first example of which is now commercially 
available, with several more systems in final stages of testing. Importantly, recent studies have 
shown the potential of reaching these targets with CGM in individuals using multiple daily 
injections (MDI) (6). In type 2 diabetes, there is generally less glycemic variability and 
hypoglycemia than in type 1 diabetes (46). Thus, people with type 2 diabetes can often achieve 
more time in target range while minimizing hypoglycemia (4). As demonstrated by Beck et al., 
individuals with type 2 diabetes increased their TIR by 10.3% (from 55.6% to 61.3%) after 24 
weeks of CGM use with slight reductions in TBR (4). Most recently, the beneficial effects of 
new medications, such as sodium glucose cotransporter-2 (SGLT-2) agents have helped 
individuals with type 1 diabetes increase TIR (49-51). Targets for type 1 diabetes and type 2 
diabetes were close enough to combine them into one set of targets, outside of pregnancy.  
 Another way to visualize the CGM-derived targets for the four categories of diabetes is 
shown in Figure 1 which displays and compares the targets for time in range (TIR - green), time 
below range (TBR - 2 categories in light and dark red) and time above range (TAR -2 categories 
in yellow and orange). It becomes clear at a glance that there are different expectations for the 
various time in ranges relating to safety concerns and efficacy based on currently available 
therapies and medical practice.  
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Figure 1. International consensus on time in range: CGM-based targets for different types of 
diabetes 
 
 
Clinical Validity of Measures 
 To fundamentally change clinical care with use of the new metrics, it would be important 
to demonstrate that the metrics relate to and predict clinical outcomes. In this regard, longer-term 
studies relating to time spent within specific CGM glycemic ranges, diabetes complications, and 
other outcomes are required. However, there is evidence from a number of recent studies that 
have shown correlations of TIR (70-180 mg/dL [3.9-10.0 mmol/L]) with diabetes complications 
(52; 53) as well as a relationship between TIR and A1C (25; 26). Although there is no evidence 
regarding time in range for older and/or high-risk individuals, numerous studies have shown the 
elevated risk for hypoglycemia in these populations (54-59). We have lowered the TIR target 
from >70% to >50% and reduced TBR to <1/%  at <70 mg/dL (<3.9 mmol/L) to place greater 
emphasis on reducing hypoglycemia with less emphasis on maintaining target glucose levels 
(Table 3). 
 
Type 1 Diabetes and Type 2 Diabetes 
Association with Complications 
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 Associations between TIR and progression of both diabetic retinopathy (DR) and 
development of microalbuminuria were reported by Beck and colleagues, using the Diabetes 
Control and Complications Trial (DCCT) data set (7-point blood glucose profiles) to validate the 
use of TIR as an outcome measure for clinical trials (53). Their analysis showed that the hazard 
rate for retinopathy progression increased by 64% for each 10% reduction in TIR. The hazard 
rate for microalbuminuria development increased by 40% for 10% reduction in TIR. A post-hoc 
analysis of the same DCCT data set showed a link between glucose of <70 mg/dL (<3.9 mmol/L) 
and <54 mg/dL (<3.0 mmol/L) and an increased risk for severe hypoglycemia (60).  
 Similar associations between DR and TIR were reported in a recent study by Lu and 
colleague in which 3,262 individuals with type 2 diabetes were evaluated for DR, which was 
graded as: non-DR; mild nonproliferative DR (NPDR); moderate NPDR; or vision-threatening 
DR (VTDR) (52). Results showed that individuals with more advanced DR spent significantly 
less time within target (70-180 mg/dL [3.9-10.0 mmol/L) and that prevalence of DR decreased 
with increasing TIR.  
 
Relationship Between TIR and A1C 
 Analyses were conducted utilizing datasets from four randomized trials encompassing 
545 adults with type 1 diabetes who had central-laboratory measurements of A1C (25). TIR (70-
180 mg/dL [3.9-10.0 mmol/L]) of 70% and 50% strongly corresponded with an A1C of 
approximately 7% (53 mmol/mol) and 8% (64 mmol/mol), respectively. An increase in TIR of 
10% (2.4 hours per day) corresponded to a decrease in A1C of approximately 0.5% (5.0 
mmol/mol); similar associations were seen in an analysis of 18 RCTs by Vigersky et al. that 
included over 2,500 individuals with type 1 diabetes and type 2 diabetes over a wide range of 
ages and A1C levels (26). (Table 4)  
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Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes 
studies 
 
Beck et al. (n=545 type 1 diabetes participants) (25) Vigersky et al. (n=1,137 type 1/type 2 participants) (26) 
TIR  
70-180 mg/dL          
(3.9-10.0 mmol/L) 
A1C 
% (mmol/mol) 
 
95% CI for 
predicted values 
TIR  
70-180 mg/dL        
(3.9-10.0 mmol/L) 
A1C 
% (mmol/mol) 
 
20% 9.4 (79) (8.0, 10.7) 20% 10.6 (92) 
30% 8.9 (74) (7.6, 10.2) 30% 9.8 (84) 
40% 8.4 (68) (7.1, 9.7) 40% 9.0 (75) 
50% 7.9 (63) (6.6, 9.2) 50% 8.3 (67) 
60% 7.4 (57) (6.1, 8.8) 60% 7.5 (59) 
70% 7.0 (53) (5.6, 8.3) 70% 6.7 (50) 
80% 6.5 (48) (5.2, 7.8) 80% 5.9 (42) 
90% 6.0 (42) (4.7, 7.3) 90% 5.1 (32) 
Every 10% increase in TIR = a0.5% (5.5 mmol/mol) A1C 
reduction 
Every 10% increase in TIR = a0.8% (8.7 mmol/mol) A1C 
reduction 
*The difference between findings from the two studies likely stems from differences in number of studies analyzed 
and subjects included (RCTs with type 1 vs. RCTs with type 1/type 2 with CGM and SMBG).  
 
Pregnancy 
 During pregnancy, the ambition is to safely increase TIR as quickly as possible, while 
reducing TAR and glycemic variability. The first longitudinal CGM data demonstrated a 13- 
percentage point increase in TIR (43% to 56% TIR 70-140 mg/dL [3.9-7.8 mmol/L]) (61). The 
TBR < 50 mg/dL reduced from 6% to 4%, although the higher TBR <70 mg/dL was high (13-
15%) using older generation sensors. With improved sensor accuracy, recent type 1 diabetes 
pregnancy studies report a lower threshold of <63 mg/dL (<3.5 mmol/L) IRU7%5DQG
mg/dL PPRO/for TIR (47; 48). Data from Sweden, and the CONCEPTT control group, 
report 50% TIR in the first trimester, improving to 60% TIR in the third trimester, reflecting 
contemporary antenatal care. Of note, these data confirm that the TBR <63 mg/dL (<3.5 
mmol/L) recommendation of <4% is safely achievable, especially after the first trimester. 
Furthermore, 33% of women achieved the recommendation of 70% TIR 63-140 mg/dL (3.5-7.8 
mmol/L) in the final (>34) weeks of pregnancy. Preliminary data suggest that closed-loop may 
allow pregnant women to safely achieve 70% TIR, at an earlier (>24 weeks) gestation (62; 63). 
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Law et al analyzed data from two early CGM trials (64; 65) describing the associations between 
CGM measures and risk of large for gestational age (LGA) infants. Taken together, the Swedish 
and CONCEPTT data confirm that a 5-7% higher TIR during the second and third trimesters is 
associated with decreased risk of LGA and neonatal outcomes, including macrosomia, shoulder 
dystocia, neonatal hypoglycemia and NICU admissions. More data are needed to define the 
clinical CGM targets for pregnant women with type 2 diabetes, who spend one third less time 
hyperglycemic than women with type 1 diabetes, and achieve TIR of 90%  (61). Because of the 
lack of evidence on CGM targets for women with GDM or type 2 diabetes in pregnancy, 
percentages of time spent in range, below range, and above range have not been included in this 
report. Recent data suggest that even more stringent targets (66) and greater attention to 
overnight glucose profiles may be required to normalize outcomes in pregnant women with 
gestational diabetes (67). 
 
Older and/or High-Risk Individuals with Diabetes  
Older and/or high-risk individuals with diabetes are at notably higher risk for severe 
hypoglycemia due to age, duration of diabetes, duration of insulin therapy, and greater 
prevalence of hypoglycemia unawareness (54-58). The increased risk of severe hypoglycemia is 
compounded by cognitive and physical impairments and other co-morbidities (56; 59). High-risk  
individuals include those with a higher risk of complications, comorbid conditions (e.g., 
cognitive deficits, renal disease, joint disease, osteoporosis, fracture, and/or cardiovascular 
disease), and often require assisted care, which can complicate treatment regimens (59). 
Therefore, when setting glycemic for high-risk and/or elderly people, it is important to 
individualize and be conservative, with a strong focus on reducing the percentage of time spent 
<70 mg/dL (<3.9 mmol/L) and preventing excessive hyperglycemia.  
 
Standardization of CGM Data Presentation  
As noted above, in 2013, a panel of clinicians with expertise in CGM published 
recommendations for use of the Ambulatory Glucose Profile (AGP) as a template for data 
presentation and visualization. Originally created by Mazze et. al. (68), the standardized AGP  
report was further developed by the International Diabetes Center and now incorporates all the 
core CGM metrics and targets along with a 14-day composite glucose profile as an integral 
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component of clinical decision making (24). This recommendation was later endorsed at the 
aforementioned international consensus conference on CGM metrics (18) and is referenced as an 
example in the American Diabetes Association (ADA) 2019 Standards of Care (16) and in an 
update to the American Association of Clinical Endocrinologists (AACE) consensus on use of 
CGM (69). The AGP report, in slightly modified formats, has been adopted by most of the CGM 
device manufacturers in their download software. An example of the AGP report, updated to 
incorporate targets, is presented in Figure 2. In the AGP report, glucose ranges are defined as 
³9HU\+LJK´/HYHO³+LJK´/HYHO³/RZ´/HYHODQG³9HU\/RZ´/HYHOA 
³PPRO/´YHUVLRQLVSURYLGHGLQSupplemental Figure 1. 
 
Figure 2. Ambulatory Glucose Profile  
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There is a general consensus that a useful CGM report is one that can be understood by 
clinician and people with diabetes. While there may be some terms (e.g., glucose variability) that 
are less familiar for many people with diabetes to understand, the value of a single-page report 
that the medical team can review and file in the electronic medical record and can be used as a 
shared decision-making tool with people with diabetes was considered to be of value (70-73). 
More detailed reports (e.g., adjustable data ranges, detailed daily reports) should remain 
available for individualized review by or with people with diabetes. 
 
Clinical Application of Time in Ranges 
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Despite its demonstrated value, clinical utilization of CGM data has remained 
suboptimal. Although time constraints and reimbursement issues are clearly obstacles, clinician 
inexperience in data interpretation and lack of standardization software for visualization of CGM 
data have also played a role (74). The proposed standardized report enables clinicians to readily 
identify important metrics such as the percentage of time spent within, below and above each 
LQGLYLGXDO¶V target range, allowing for greater personalization of therapy through shared decision 
making. 
Using the standardized report the clinician can also address glucose variability (e.g., 
%CV metric) (75) or use glucose management indicator (GMI) metric (43) to discuss the 
possible discrepancies noted in glucose exposure derived from CGM data versus the LQGLYLGXDO¶V 
laboratory-measured A1C (40; 76). With appropriate educational materials, time and experience, 
clinicians will develop a systematic approach to CGM data analysis and the most effective ways 
to discuss the data with patients in person or remotely.   
 
Goal Setting 
 Numerous studies have demonstrated the clinical benefits of early achievement of near-
normal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83). 
However, when advising people with diabetes, goal-setting must be collaborative and take into 
account the individual needs/capabilities of each patient and start with the goals that are most 
achievable. An early study by DeWalt and colleagues found that setting small, achievable goals 
not only enhances SHRSOH¶V ability to cope with their diabetes, but that people with diabetes who 
set and achieved their goals often initiated additional behavioral changes on their own (84). One 
approach to consider is the S.M.A.R.T. Goal (Specific, Measurable, Achievable, Relevant, Time 
bound) intervention, which is directly applicable to setting targets for times in ranges. First 
described by Lawlor and Hornyak in 2012 (85), this approach incorporates four key components 
of behavioral change relevant to goal setting: 1) the goal is specific and defines exactly what is to 
be achieved; 2) the goal is measurable and there is tangible evidence when it has been achieved; 
3) the goal is achievable but stretches the patient slightly so that he/she feels challenged; and 4) 
the goal should be attainable over a short period of time.  
Effective goals should utilize CGM data to identify specific instances for the patient to 
take measurable action to prevent hypoglycemia. Although analysis of the AGP reports provides 
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an opportunity for meaningful discussion, individuals should be counseled to look at patterns 
throughout the day to see when low glucose events are occurring and make adjustments in their 
therapy to reduce these events.  
When applying the CGM metrics in clinical practice, it may be more meaningful and 
motivating to communicate to people with diabetes the importance of working to reduce the time 
spent <70 mg/dL (<3.9 mmol/L) to less than one hour per day and less than 15 minutes per day 
<54 mg/dL (<3.0 mmol/L) rather than using <4% and <1% respectively, as the goal. However, as 
discussed earlier, targets must be personalized to meet the needs and capabilities of each person, 
focusing on small steps and small successes. Individuals with diabetes should work with their 
physician and/or educator to develop a SMART goal to reduce time below range.  
Individualized goals are particularly important for pediatric and young adult populations. 
The International Society for Pediatric Diabetes (ISPAD) recommends that targets for  
individuals years aim for the lowest achievable A1C without undue exposure to severe 
hypoglycemia balances with quality of life and burden of care (86). An A1C target of 7.0% (53 
mmol/mol) can be used in children, adolescents and adults years who have access to 
comprehensive care (86).  However, a higher A1C goal (e.g., <7.5% [<58 mmol/mol] may be 
more appropriate in the following situations: inability to articulate hypoglycemia symptoms; 
hypoglycemia; hypoglycemia unawareness; history of severe hypoglycemia, lack of access to 
analog insulins and/or advanced insulin delivery technology, inability to regularly check glucose 
(86). This would equate to a TIR target of  ~60% (Table 4).  
 The consensus group recognized that achieving the targets for the various time in ranges 
is aspirational in some situations and many individuals will require ongoing support, both 
educational and technological, from their healthcare team. Importantly, as demonstrated by Beck 
et al. (25), Vigersky et al. (26) and Feig et al. (47), even small, incremental improvements yield 
significant glycemic benefits. Therefore, when advising individuals with diabetes (particularly 
children, adolescents, high-risk) about their glycemic goals, it important to take a step-wise 
approach, emphasizing that what may appear to be small, incremental successes (e.g. 5% 
increase in TIR) are, in fact, clinically significant in improving their glycemic control (25; 26; 
47). However, when counseling women planning pregnancy and pregnant women, greater 
emphasis should be placed on getting to goal as soon as possible (47; 48). 
 
 21 
Conclusions 
 Use of CGM continues to expand in clinical practice. As a component of diabetes self-
management, daily use of CGM provides the ability to obtain immediate feedback on current 
glucose levels, direction and rate of change in glucose levels. This information allows people 
with diabetes to optimize dietary intake and exercise, make informed therapy decisions regarding 
meal-time and correction of insulin dosing and, importantly, react immediately and appropriately 
to mitigate or prevent acute glycemic events (87-89). Retrospective analysis of CGM data, 
utilizing standardized data management tools such as the AGP, enables clinicians and people 
with diabetes to work collaboratively in identifying problem areas and then set achievable goals 
(71-73). We conclude that, in clinical practice, time in ranges (within target range, below range, 
above range) are both appropriate and useful as clinical targets and outcome measurements that 
complement A1C for a wide range of people with diabetes, and that the target values specified in 
this paper should be considered an integral component of CGM data analysis and day-to-day 
treatment decision making. 
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